Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1984-6-29
pubmed:abstractText
Forty-four evaluable patients with metastatic malignant melanoma confined to the skin, subcutaneous tissues, lymph nodes, and/or lung were randomly assigned to receive either 1 X 10(6), 3 X 10(6), or 9 X 10(6) units of partially purified human leukocyte (alpha) interferon by daily im injection for 42 days. One patient achieved a partial response, two had minor responses, and three others had mixed responses. The only partial response was observed at the lowest dose of interferon. Toxicity increased in frequency and intensity with increasing interferon dose. This preparation of interferon at the doses, route, and schedule used appears to have little efficacy in metastatic malignant melanoma.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0361-5960
pubmed:author
pubmed:issnType
Print
pubmed:volume
68
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
723-6
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:6722830-Adolescent, pubmed-meshheading:6722830-Adult, pubmed-meshheading:6722830-Aged, pubmed-meshheading:6722830-Dose-Response Relationship, Immunologic, pubmed-meshheading:6722830-Evaluation Studies as Topic, pubmed-meshheading:6722830-Female, pubmed-meshheading:6722830-Fever, pubmed-meshheading:6722830-Humans, pubmed-meshheading:6722830-Hypotension, pubmed-meshheading:6722830-Immunotherapy, pubmed-meshheading:6722830-Interferon Type I, pubmed-meshheading:6722830-Leukocytes, pubmed-meshheading:6722830-Lung Neoplasms, pubmed-meshheading:6722830-Lymphatic Metastasis, pubmed-meshheading:6722830-Male, pubmed-meshheading:6722830-Melanoma, pubmed-meshheading:6722830-Middle Aged, pubmed-meshheading:6722830-Nausea, pubmed-meshheading:6722830-Random Allocation, pubmed-meshheading:6722830-Skin Neoplasms
pubmed:year
1984
pubmed:articleTitle
Human leukocyte (alpha) interferon in metastatic malignant melanoma: the American Cancer Society phase II trial.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't